Berkeley Lights

Berkeley Lights did not operate as an investment firm — it was a commercial life-sciences tools company. Product and capital-allocation decisions were led by CEO Eric Hobbs and the executive team, overseen by a board of directors that included representation from venture investors prior to the 2020 IPO.

Commercial adoption was driven by direct sales and collaborations with large biopharma, academic cell-biology labs, and contract research organizations. Named users included Pfizer, Genentech, Gilead, and BioMarin. The firm also co-published application data with partners to demonstrate platform utility for antibody discovery and cell-line development workflows.

Neither. Berkeley Lights was a publicly traded life-sciences tools company (Nasdaq: BLI) from July 2020 until its acquisition by Bruker Corporation in 2023. It was originally venture-backed by investors including Walden-Riverwood Ventures, Sequoia Capital, and DAG Ventures before the IPO.

Berkeley Lights itself was not an institutional allocator and did not deploy capital into external stages or asset classes. Its business was selling genetic-analysis and cell-manipulation instruments — plus associated consumables and software — into the pharmaceutical and academic R&D markets.

Bruker Corporation, a publicly traded scientific-instruments company, acquired Berkeley Lights for approximately $108 million in cash in a transaction announced in May 2023 and completed later that year. Post-acquisition, Berkeley Lights operates as part of Bruker's life-sciences tools segment.

The primary beneficiaries are therapeutic antibody discovery, cell-line development for biomanufacturing, and functional cell-based assays used in immunology and oncology research. Adjacent applications include T-cell phenotyping and rare-cell isolation for cell therapy workflows.

Because Berkeley Lights functioned as a product company rather than a fund, its partnership model centered on technology access agreements and collaborative application development with biopharma customers. It did not participate in co-investment vehicles, deal-by-deal SPVs, or fund commitments.